Abbvie Inc.

James Patrick Stambuli

Philip R Kym

Valentino J Stella

Geoff G Zhang

Peter T Mayer

Eric A Voight

Mark A Matulenko

Vincent S Chan

Yanbin Lao

Xiaochun Lou

Ye Huang

Sean E Mackey

Zhi Wang

Russell C Klix

Christopher P Miller

Brian P Enright

Benoit Cardinal-David

Alexander D Huters

Scott W Krabbe

Rodger F Henry

Michael Z Hoemann

Maria A Argiriadi

Kevin Patrick Cusack

Raimundo Ho

David Andrew Kinsman

Kassibla E Dempah

Ciaran O'Reilly

Hannah Dexter

Sami Osman

Euan Fordyce

Steve St Gallay

Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, useful as RIPK1 inhibitors, and pharmaceutical compositions comprising same. Further provided are methods of use and preparation. Also provided are methods of treating Ulcerative Colitis using a compound of Formula (I).

Nicotinamide RIPK1 inhibitors

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

Carbidopa and L-dopa prodrugs and methods of use

Growing community of inventors

Worcester, MA, United States of America

James Patrick Stambuli